Compare FLO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLO | CRVS |
|---|---|---|
| Founded | 1919 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2000 | 2016 |
| Metric | FLO | CRVS |
|---|---|---|
| Price | $6.17 | $13.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $11.20 | ★ $30.17 |
| AVG Volume (30 Days) | ★ 6.5M | 649.1K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.16% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $5,256,479,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.65 | N/A |
| P/E Ratio | $16.21 | ★ N/A |
| Revenue Growth | ★ 3.00 | N/A |
| 52 Week Low | $6.10 | $5.64 |
| 52 Week High | $14.41 | $26.95 |
| Indicator | FLO | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 27.88 | 37.61 |
| Support Level | N/A | $12.76 |
| Resistance Level | $8.86 | $14.00 |
| Average True Range (ATR) | 0.30 | 0.62 |
| MACD | -0.08 | -0.13 |
| Stochastic Oscillator | 5.94 | 8.89 |
Flowers Foods Inc operates as a producer and marketer of packaged bakery foods in the United States. Its principal products include breads, buns, rolls, snack items (bars, cakes, cookies, and crackers), bagels, English muffins, tortillas, and baking mixes. These products are sold under the brand names Nature's Own, Dave's Killer Bread (DKB), Canyon Bakehouse, Simple Mills, Wonder, and Tastykake. The company derives the majority of its revenue from the sales of its bakery products.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.